^
BIOMARKER:

PD-L1 overexpression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Mesothelioma
pembrolizumab + nintedanib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
HCC
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
CRC
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
Sanofi Press Release - 4 weeks
PD-L1 overexpression
Oral Cancer
pembrolizumab
Sensitive: C4 – Case Studies
Oral Oncol - 4 weeks
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
PD-L1 overexpression
Urothelial Cancer
tislelizumab
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
NSCLC
bevacizumab + atezolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
NSCLC
bevacizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive: A2 - Guideline
PD-L1 overexpression
NSCLC
atezolizumab + MTIG7192A
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
carboplatin + gemcitabine
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
cisplatin + albumin-bound paclitaxel
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
GC
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
carboplatin + pemetrexed
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
cisplatin + pemetrexed
Sensitive: B - Late Trials
PD-L1 overexpression
GastroEsophageal Cancer
PD1 inhibitor
Sensitive: B - Late Trials
PD-L1 overexpression
GastroEsophageal Cancer
PD-L1 inhibitor
Sensitive: B - Late Trials
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
tislelizumab
Sensitive: B - Late Trials
PD-L1 overexpression
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
nivolumab
Sensitive: B - Late Trials
PD-L1 overexpression
NSCLC
avelumab
Sensitive: B - Late Trials
PD-L1 overexpression
SCCHN
durvalumab
Sensitive: B - Late Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 overexpression
Gastric Cancer
pembrolizumab
Sensitive: B - Late Trials
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: B - Late Trials
PD-L1 overexpression
Ovarian Cancer
atezolizumab
Sensitive: C1 - Off-label
PD-L1 overexpression
Urothelial Cancer
PF-06801591
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
Sarcoma
nivolumab + ipilimumab
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
NSCLC
durvalumab
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
NSCLC
pembrolizumab + niraparib
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
SCCHN
pembrolizumab
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
LUAD
pembrolizumab
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
NSCLC
INCMGA0012
Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
camrelizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Peripheral T-cell Lymphoma
GB226
Sensitive: C3 – Early Trials
PD-L1 overexpression
Diffuse Large B Cell Lymphoma
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
durvalumab + CP-675206
Sensitive: C3 – Early Trials
PD-L1 overexpression
Prostate Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
Gastric Cancer
trastuzumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
NHL
avelumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Triple Negative Breast Cancer
olaparib
Sensitive: C3 – Early Trials
PD-L1 overexpression
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
SCCHN
PD1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
NHL
AB122
Sensitive: C3 – Early Trials
PD-L1 overexpression
Diffuse Large B Cell Lymphoma
MGD013
Sensitive: C3 – Early Trials
PD-L1 overexpression
Bladder Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
LUAD
pemetrexed
Sensitive: C3 – Early Trials
PD-L1 overexpression
Thyroid Gland Carcinoma
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials
PD-L1 overexpression
Solid Tumor
avelumab + IMP 321
Sensitive: C3 – Early Trials
PD-L1 overexpression
Solid Tumor
IMP 321
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
PF-06801591
Sensitive: C3 – Early Trials
PD-L1 overexpression
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
Gastric Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
pembrolizumab + LY3500518
Resistant: C3 – Early Trials
PD-L1 overexpression
Melanoma
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Head and Neck Cancer
nivolumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
M7824
Sensitive: C3 – Early Trials
PD-L1 overexpression
Melanoma
ipilimumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Melanoma
nivolumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Ovarian Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
SCCHN
olaparib
Resistant: C3 – Early Trials
PD-L1 overexpression
SCCHN
durvalumab + CP-675206
Sensitive: C3 – Early Trials
PD-L1 overexpression
Oral Cancer
nivolumab + MGCD516
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
EGFR inhibitor
Resistant: C3 – Early Trials
PD-L1 overexpression
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
ipilimumab + cemiplimab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
AB122
Sensitive: C3 – Early Trials
PD-L1 overexpression
Nasopharyngeal Carcinoma
AB122
Sensitive: C3 – Early Trials
PD-L1 overexpression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
PD-L1 overexpression
SCCHN
pembrolizumab + afatinib
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
AB122 + AB154 + AB928
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
AB122 + AB154
Sensitive: C3 – Early Trials
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 overexpression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Gastric Cancer
SHR-1701
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
SHR-1701
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
anlotinib + AK104
Sensitive: C3 – Early Trials
PD-L1 overexpression
NSCLC
toripalimab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
Cervical Cancer
pembrolizumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Esophageal Adenocarcinoma
durvalumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
durvalumab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: C3 – Early Trials
PD-L1 overexpression
Malignant Pleural Mesothelioma
nivolumab
Sensitive: C4 – Case Studies